BlackRock’s Heron Therapeutics HRTX Stock Holding History

BlackRock’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.09M	Sell	10,106,422 -111,814	-1%	-$130K	﹤0.01%	3628
2025 Q4	$13.3M	Buy	10,218,236 +230,776	+2%	+$285K	﹤0.01%	3322
2025 Q3	$12.6M	Sell	9,987,460 -114,255	-1%	-$181K	﹤0.01%	3333
2025 Q2	$20.9M	Buy	10,101,715 +1,538,296	+18%	+$3.14M	﹤0.01%	2995
2025 Q1	$18.8M	Sell	8,563,419 -27,323	-0.3%	-$53K	﹤0.01%	2979
2024 Q4	$13.1M	Buy	8,590,742 +56,175	+0.7%	+$91K	﹤0.01%	3281
2024 Q3	$17M	Buy	8,534,567 +209,182	+3%	+$499K	﹤0.01%	3142
2024 Q2	$29.1M	Buy	8,325,385 +1,039,357	+14%	+$3.19M	﹤0.01%	2754
2024 Q1	$20.2M	Buy	7,286,028 +123,676	+2%	+$311K	﹤0.01%	2992
2023 Q4	$12.2M	Sell	7,162,352 -964,497	-12%	-$1.06M	﹤0.01%	3286
2023 Q3	$8.37M	Sell	8,126,849 -249,719	-3%	-$355K	﹤0.01%	3442
2023 Q2	$9.72M	Sell	8,376,568 -1,024,516	-11%	-$1.83M	﹤0.01%	3432
2023 Q1	$14.2M	Sell	9,401,084 -249,625	-3%	-$625K	﹤0.01%	3142
2022 Q4	$24.1M	Buy	9,650,709 +392,406	+4%	+$1.26M	﹤0.01%	2926
2022 Q3	$39.1M	Buy	9,258,303 +462,403	+5%	+$1.81M	﹤0.01%	2633
2022 Q2	$24.5M	Buy	8,795,900 +639,769	+8%	+$2.57M	﹤0.01%	2975
2022 Q1	$46.6M	Buy	8,156,131 +473,930	+6%	+$3.47M	﹤0.01%	2636
2021 Q4	$70.1M	Buy	7,682,201 +9,333	+0.1%	+$95.3K	﹤0.01%	2431
2021 Q3	$82M	Buy	7,672,868 +151,019	+2%	+$1.84M	﹤0.01%	2339
2021 Q2	$117M	Buy	7,521,849 +384,539	+5%	+$6.12M	﹤0.01%	2160
2021 Q1	$116M	Buy	7,137,310 +250,378	+4%	+$4.46M	﹤0.01%	2109
2020 Q4	$146M	Buy	6,886,932 +1,060,614	+18%	+$18.4M	﹤0.01%	1839
2020 Q3	$86.3M	Sell	5,826,318 -491,236	-8%	-$7.66M	﹤0.01%	1968
2020 Q2	$92.9M	Buy	6,317,554 +667,378	+12%	+$11M	﹤0.01%	1878
2020 Q1	$66.3M	Sell	5,650,176 -118,026	-2%	-$2.22M	﹤0.01%	1899
2019 Q4	$136M	Buy	5,768,202 +693,516	+14%	+$15.3M	0.01%	1770
2019 Q3	$93.9M	Buy	5,074,686 +173,294	+4%	+$3.19M	﹤0.01%	1939
2019 Q2	$91.1M	Buy	4,901,392 +42,657	+0.9%	+$852K	﹤0.01%	1974
2019 Q1	$119M	Sell	4,858,735 -54,271	-1%	-$1.42M	0.01%	1766
2018 Q4	$127M	Buy	4,913,006 +132,207	+3%	+$3.63M	0.01%	1637
2018 Q3	$151M	Buy	4,780,799 +236,068	+5%	+$8.79M	0.01%	1673
2018 Q2	$177M	Buy	4,544,731 +1,032,010	+29%	+$32.9M	0.01%	1560
2018 Q1	$97M	Buy	3,512,721 +535,285	+18%	+$12.1M	﹤0.01%	1872
2017 Q4	$53.9M	Buy	2,977,436 +91,012	+3%	+$1.48M	﹤0.01%	2243
2017 Q3	$46.6M	Buy	2,886,424 +89,873	+3%	+$1.41M	﹤0.01%	2337
2017 Q2	$38.7M	Buy	2,796,551 +141,706	+5%	+$2.05M	﹤0.01%	2409
2017 Q1	$39.8M	Buy	2,654,845 +2,652,008	+93,479%	+$36.7M	﹤0.01%	2364
2016 Q4	$37K	Sell	2,837 -789	-22%	-$12.4K	﹤0.01%	3061
2016 Q3	$62K	Sell	3,626 -478	-12%	-$8.87K	﹤0.01%	2863
2016 Q2	$74K	Buy	4,104 +1,991	+94%	+$38.9K	﹤0.01%	2729
2016 Q1	$41K	Buy	2,113 +1,348	+176%	+$26.6K	﹤0.01%	2470
2015 Q4	$20K	Sell	765 -289	-27%	-$7.73K	﹤0.01%	2578
2015 Q3	$26K	Buy	1,054 +500	+90%	+$16.7K	﹤0.01%	2230
2015 Q2	$17K	Hold	554	–	–	﹤0.01%	2473
2015 Q1	$8K	Hold	554	–	–	﹤0.01%	2841
2014 Q4	$6K	Hold	554	–	–	﹤0.01%	3001
2014 Q3	$5K	Hold	554	–	–	﹤0.01%	3070
2014 Q2	$7K	Buy	+554	New	+$6.62K	﹤0.01%	2999

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.29B AUM 38.13% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

CPC

Congress Park Capital Saratoga Springs, New York $326M AUM 16.2% 1-Year Est. Return